Goldman Sachs Put 95 NOVN 20.09.2.../ DE000GG96D65 /
2024-06-28 10:24:51 AM | Chg.-0.020 | Bid3:43:19 PM | Ask3:43:19 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.250EUR | -7.41% | 0.250 Bid Size: 50,000 |
0.260 Ask Size: 50,000 |
NOVARTIS N | 95.00 CHF | 2024-09-20 | Put |
GlobeNewswire
1:00 PM
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...
GlobeNewswire
06-27
XEALTH LAUNCHES DEWEY, THE INDUSTRY’S FIRST PERFORMANCE-BASED, DIGITAL HEALTH BENCHMARKING TOOL
GlobeNewswire
06-26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
06-13
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
04-16
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
03-14
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
02-28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
01-10
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
01-05
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
01-02
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
2023-12-11
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire
2023-12-08
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...